Genscript Biotech Corporation (G51) - Net Assets
Based on the latest financial reports, Genscript Biotech Corporation (G51) has net assets worth €4.42 Billion EUR (≈ $5.17 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.43 Billion ≈ $6.35 Billion USD) and total liabilities (€1.01 Billion ≈ $1.18 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genscript Biotech Corporation asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.42 Billion |
| % of Total Assets | 81.35% |
| Annual Growth Rate | 48.38% |
| 5-Year Change | 430.09% |
| 10-Year Change | N/A |
| Growth Volatility | 49.57 |
Genscript Biotech Corporation - Net Assets Trend (2016–2024)
This chart illustrates how Genscript Biotech Corporation's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Genscript Biotech Corporation for the complete picture of this company's asset base.
Annual Net Assets for Genscript Biotech Corporation (2016–2024)
The table below shows the annual net assets of Genscript Biotech Corporation from 2016 to 2024. For live valuation and market cap data, see G51 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
+111.48% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
+50.03% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
+24.68% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
+34.01% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
+119.07% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
-24.53% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
+116.06% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
+24.07% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genscript Biotech Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2791.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.35 Billion | 54.39% |
| Other Components | €1.97 Billion | 45.61% |
| Total Equity | €4.32 Billion | 100.00% |
Genscript Biotech Corporation Competitors by Market Cap
The table below lists competitors of Genscript Biotech Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marex Group plc Ordinary Shares
NASDAQ:MRX
|
$3.01 Billion |
|
Metro Brands Limited
NSE:METROBRAND
|
$3.01 Billion |
|
ZF Commercial Vehicle Control Systems India Limited
NSE:ZFCVINDIA
|
$3.02 Billion |
|
Valeo SA
PA:FR
|
$3.02 Billion |
|
Standex International Corporation
NYSE:SXI
|
$3.01 Billion |
|
Chengdu Xingrong Investment Co Ltd
SHE:000598
|
$3.01 Billion |
|
AIR CHINA LTD H ADR/20
F:AD2B
|
$3.01 Billion |
|
Virbac SA
PA:VIRP
|
$3.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genscript Biotech Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,391,079,000 to 4,321,172,000, a change of 2,930,093,000 (210.6%).
- Net income of 2,961,877,000 contributed positively to equity growth.
- New share issuances of 13,486,000 increased equity.
- Other factors decreased equity by 45,270,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.96 Billion | +68.54% |
| Share Issuances | €13.49 Million | +0.31% |
| Other Changes | €-45.27 Million | -1.05% |
| Total Change | €- | 210.63% |
Book Value vs Market Value Analysis
This analysis compares Genscript Biotech Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 11.70x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.13 | €1.47 | x |
| 2018-12-31 | €0.26 | €1.47 | x |
| 2019-12-31 | €0.20 | €1.47 | x |
| 2020-12-31 | €0.46 | €1.47 | x |
| 2021-12-31 | €0.42 | €1.47 | x |
| 2022-12-31 | €0.48 | €1.47 | x |
| 2023-12-31 | €0.66 | €1.47 | x |
| 2024-12-31 | €2.02 | €1.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genscript Biotech Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 68.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 498.22%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.22x
- Recent ROE (68.54%) is above the historical average (-1.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.73% | 22.81% | 0.51x | 1.27x | €8.41 Million |
| 2017 | 11.99% | 17.11% | 0.30x | 2.32x | €4.34 Million |
| 2018 | 4.43% | 9.18% | 0.25x | 1.92x | €-26.65 Million |
| 2019 | -25.32% | -35.45% | 0.31x | 2.32x | €-135.19 Million |
| 2020 | -22.73% | -52.51% | 0.27x | 1.61x | €-295.12 Million |
| 2021 | -39.54% | -68.13% | 0.23x | 2.54x | €-435.84 Million |
| 2022 | -22.45% | -36.26% | 0.25x | 2.52x | €-327.91 Million |
| 2023 | -6.86% | -17.03% | 0.17x | 2.44x | €-234.58 Million |
| 2024 | 68.54% | 498.22% | 0.11x | 1.22x | €2.53 Billion |
Industry Comparison
This section compares Genscript Biotech Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,057,695,497
- Average return on equity (ROE) among peers: -39.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genscript Biotech Corporation (G51) | €4.42 Billion | 14.73% | 0.23x | $3.01 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Lif… Read more